XML 91 R77.htm IDEA: XBRL DOCUMENT v3.25.0.1
Collaboration and License Agreements - Additional Information (Details)
 1 Months Ended 12 Months Ended
Nov. 30, 2023
USD ($)
Oct. 31, 2023
USD ($)
shares
Sep. 30, 2022
USD ($)
shares
Jun. 30, 2022
USD ($)
Jan. 31, 2022
USD ($)
Dec. 31, 2021
USD ($)
Oct. 31, 2021
USD ($)
Jul. 31, 2021
USD ($)
Jun. 30, 2021
USD ($)
Apr. 30, 2019
USD ($)
shares
Dec. 31, 2024
USD ($)
shares
Dec. 31, 2023
USD ($)
Dec. 31, 2022
USD ($)
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                          
Current portion of deferred revenue                     $ 108,858,000 $ 68,706,000  
Long-term portion of deferred revenue                     33,218,000 109,888,000  
Deferred revenue liability                     142,076,000 178,594,000 $ 338,153,000
Research and development expense                     367,561,000 437,381,000 311,594,000
Gain (loss) from equity method investment                         (25,500,000)
Revenue                     63,518,000 377,709,000 60,920,000
Carrying value of equity method investment                     $ 0 0  
Verve Therapeutics, Inc. | Common Stock                          
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                          
Equity shares held | shares                     546,970    
Lilly Agreement                          
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                          
Sale and issuance of common stock | shares   2,004,811                      
Aggregated purchase price   $ 50,000,000                      
Stock purchase agreement amount received   $ 50,000,000                      
Agreement description   In October 2023, the Company entered into a Transfer and Delegation Agreement, or the Lilly Agreement, with Eli Lilly and Company, or Lilly, pursuant to which Lilly acquired certain assets and other rights under the Company’s amended collaboration and license agreement, or the Verve Agreement, with Verve Therapeutics, Inc., or Verve, including the Company’s opt-in rights to co-develop and co-commercialize Verve’s base editing programs for cardiovascular disease (see discussion below related to the Verve Agreement). The Company granted Lilly an exclusive sublicense to the Verve technology originally licensed to the Company under the Verve Agreement. Lilly also acquired the right to receive any future milestone or royalty payments payable by Verve under the Verve Agreement and the rights and obligations to designate representatives and participate on the joint steering committee with Verve. The Company received a $200.0 million nonrefundable upfront payment and is eligible to receive up to $350.0 million in potential future development-stage payments upon the completion of certain clinical, regulatory and alliance events.                      
Collaboration agreement upfront payment received $ 200,000,000                        
Collaboration agreement performance obligation revenue recognized                     $ 25,000,000 216,400,000  
Collaboration agreement aggregate transaction price   $ 216,400,000                      
Collaboration agreement term of contract   6 years                      
Deferred revenue liability                     0    
Lilly Agreement | Maximum                          
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                          
Additional proceeds from potential future development-stage payments   $ 350,000,000                      
Lilly Agreement | Common Stock                          
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                          
Fair value of common stock sold   16,400,000                      
Collaboration license agreement fair value of shares issued   33,600,000                      
Pfizer                          
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                          
Agreement description           In December 2021, the Company entered into a research collaboration agreement, or the Pfizer Agreement, with Pfizer Inc., or Pfizer, focused on the use of certain of the Company’s base editing technology to develop in vivo therapies for rare genetic diseases of the liver, muscle, and central nervous system. Under the terms of the Pfizer Agreement, the Company will conduct all research activities through development candidate selection for three base editing programs that target specific genes corresponding to specific diseases that are the subject of such programs. Pfizer will have exclusive rights to license each of the three programs at no additional cost, each an Opt-In Right, and will assume responsibility for subsequent development and commercialization. At the end of the Phase 1/2 clinical trials, the Company may elect to enter into a global co-development and co-commercialization agreement with Pfizer with respect to one program licensed under the collaboration for an option exercise fee equal to a percentage of the applicable development costs incurred by Pfizer, or the Participation Election. In the event the Company elects to exercise its Participation Election, upon the payment of its option exercise fee, Pfizer and the Company would share net profits as well as development and commercialization costs in a 65%/35% (Pfizer/Company) split for such program. The research collaboration is managed on an overall basis by a Joint Research Committee, or JRC, formed by an equal number of representatives from the Company and Pfizer.              
Collaboration arrangement, initial term           4 years              
Collaboration arrangement extension term description           extended for an additional year on a program-by-program basis              
Potential total consideration           $ 1,350,000,000              
Nonrefundable upfront payment receivable           300,000,000              
Collaboration agreement upfront payment received         $ 300,000,000                
Collaboration agreement performance obligation revenue recognized                     8,400,000 134,300,000 48,200,000
Collaboration agreement aggregate transaction price           $ 300,000,000              
Current portion of deferred revenue                     88,500,000    
Long-term portion of deferred revenue                     20,600,000    
Earn-out payment period           10 years              
Deferred revenue liability           $ 300,000,000              
Pfizer | Assigned to Company | Upon Participation Election                          
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                          
Net profits as well as development and commercialization costs percentage           35.00%              
Pfizer | Assigned to Pfizer | Upon Participation Election                          
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                          
Net profits as well as development and commercialization costs percentage           65.00%              
Pfizer | Maximum | Per Program                          
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                          
Development regulatory and commercial milestones receivable           $ 350,000,000              
Sana Biotechnology                          
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                          
Collaboration agreement performance obligation revenue recognized                     2,000,000 1,800,000 0
License agreement upfront payment received             $ 50,000,000            
Collaboration agreement aggregate transaction price             50,000,000            
Additional fee per additional option right             15,000,000            
Option rights aggregate potential additional consideration             30,000,000            
Sana Biotechnology | Maximum                          
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                          
Development regulatory and commercial milestones receivable             $ 65,000,000            
Sana Biotechnology | License Agreement Terms                          
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                          
Agreement description             For up to forty-two months following the effective date of the Sana Agreement, Sana has the option to select up to a cumulative total of two additional CAR antigen targets or PSC product types for an additional fee of $15.0 million per additional CAR antigen target and additional PSC product type, or the Option Rights, for an aggregate potential additional consideration of $30.0 million. Further, for up to thirty months following the effective date of the Sana Agreement, Sana has a one-time right to substitute, in the aggregate, either one CAR antigen target or one PSC product type at no additional cost, or the Replacement Right. Sana may also select a specified number of additional or replacement genetic targets for each PSC product type at any time prior to the third anniversary of the effective date at no additional cost, or the Genetic Target Nomination Rights. Sana may terminate the Sana Agreement for convenience prior to the first commercial sale of any licensed product by providing 90 days’ prior written notice or upon 180 days’ prior written notice after first commercial sale.            
Apellis Pharmaceuticals, Inc                          
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                          
Agreement description                 In June 2021, the Company entered into a research collaboration agreement, or the Apellis Agreement, with Apellis Pharmaceuticals, Inc., or Apellis, focused on the use of certain of the Company’s base editing technology to discover new treatments for complement system-driven diseases. Under the terms of the Apellis Agreement, the Company will conduct preclinical research on up to six base editing programs that target specific genes within the complement system in various organs, including the eye, liver, and brain. Apellis has an exclusive option to license any or all of the six programs, or in each case, an Opt-In Right, and will assume responsibility for subsequent development. The Company may elect to enter into a 50-50 U.S. co-development and co-commercialization agreement with Apellis with respect to one program instead of a license. The collaboration is managed on an overall basis by an alliance steering committee formed by an equal number of representatives from the Company and Apellis.        
Collaboration arrangement, initial term                 5 years        
Upfront revenue recognized                 $ 0        
Collaboration agreement performance obligation revenue recognized                     19,700,000 16,400,000 10,600,000
Collaboration agreement aggregate transaction price                 75,000,000        
Upfront fee receivable upon signing contract                 50,000,000        
Collaboration agreement first anniversary amount receivable       $ 25,000,000         $ 25,000,000        
Upfront payment received under term of agreement               $ 50,000,000          
Collaboration agreement first anniversary payment received       $ 25,000,000                  
Current portion of deferred revenue                     14,000,000    
Long-term portion of deferred revenue                     12,600,000    
Apellis Pharmaceuticals, Inc | Maximum                          
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                          
Collaboration arrangement extension term                 2 years        
Verve                          
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                          
Remaining unrecognized revenue recognized   $ 300,000                      
Agreement description                   In April 2019, the Company entered into a collaboration and license agreement with Verve, or the Verve Agreement, to investigate gene editing strategies to modify genes associated with an increased risk of coronary diseases and in July 2022, the Company and Verve amended the Verve Agreement. Under the terms of the Verve Agreement, as amended, the Company granted Verve an exclusive license to certain base editor technology and improvements and Verve granted the Company a non-exclusive license under certain know-how and patents controlled by Verve, an interest in joint collaboration technology and a non-exclusive license under certain delivery technology.      
Collaboration agreement performance obligation revenue recognized                     0 400,000  
Deferred revenue liability                     0    
Upfront payment fair value shares received                   $ 500,000      
Reverse stock split ratio                 9.2592        
Reverse stock split                 one-for-9.2592        
Equity shares value held                     3,100,000    
Verve | Maximum                          
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                          
Collaboration agreement performance obligation revenue recognized                         100,000
Verve | Common Stock                          
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                          
Collaboration license agreement fair value of shares received                   $ 500,000      
Number of common stock received | shares                   2,600,000      
Orbital                          
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                          
Common stock shares received at closing | shares     75,000,000                    
Agreement description     Under the terms of the Orbital Agreement, the Company will collaborate with Orbital to advance nonviral delivery and ribonucleic acid, or RNA, technology by providing Orbital with certain proprietary materials, a non-exclusive research license to certain RNA technology and nonviral delivery technology controlled by the Company, and by performing research and development support services as outlined in a research plan. The Company also granted Orbital an exploitation license to certain RNA technology and nonviral delivery technology controlled by the Company. The exploitation license is exclusive in the fields of vaccines and certain protein therapeutics and nonexclusive in all other fields other than gene editing and conditioning. The collaboration is managed on an overall basis by a Joint Steering Committee, or JSC, comprised of an equal number of representatives from the Company and Orbital.                    
Collaboration agreement performance obligation revenue period for recognition     3 years                    
Collaboration agreement aggregate transaction price     $ 25,500,000                    
Collaboration agreement performance obligation revenue recognized                     8,500,000 8,500,000 2,100,000
Collaboration agreement aggregate transaction price     25,500,000                    
Current portion of deferred revenue                     6,400,000    
Gain (loss) from equity method investment                     $ 0 $ 0 $ (25,500,000)
Carrying value of equity method investment     $ 0                    
Orbital | Research Plan                          
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                          
Collaboration arrangement, initial term     3 years                    
Orbital | Exploitation Licenses                          
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                          
Collaboration arrangement, initial term     3 years                    
Collaboration arrangement extension term description     which may be extended for up to two successive one-year periods                    
Orbital | Option Pricing Model | Level 3 | Volatility of Market Participants                          
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                          
Alternate investment, measurement input     0.68                    
Orbital | Option Pricing Model | Level 3 | Discount for Lack of Marketability                          
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                          
Alternate investment, measurement input     0.43